CST3 and GDF15 ameliorate renal fibrosis by inhibiting fibroblast growth and activation

Area of Science:

• Nephrology
• Cell Biology
• Biochemistry

Background:

• End-stage renal fibrosis necessitates treatments like dialysis and transplantation, which are invasive and have long-term complications.
• Developing novel therapeutic strategies to delay renal fibrosis progression is crucial for improving patient outcomes.

Purpose of the Study:

• To identify cytokines with anti-fibrotic activity.
• To investigate the therapeutic potential of Cystatin C (CST3) and Growth Differentiation Factor 15 (GDF15) in ameliorating renal fibrosis.

Main Methods:

• Cytokine array screening to identify anti-fibrotic candidates.
• In vitro experiments using primary mouse kidney fibroblasts to assess cytokine effects on apoptosis and collagen production.
• In vivo studies using a mouse model of unilateral ureter obstruction-induced fibrosis.

Main Results:

• Cystatin C (CST3) and Growth Differentiation Factor 15 (GDF15) demonstrated anti-fibrotic activity by inducing apoptosis and reducing collagen production in fibroblasts.
• Co-administration of CST3 and GDF15 synergistically enhanced anti-fibrotic effects.
• Both cytokines, individually and in combination, significantly reduced fibrotic burden in vivo.
• Mechanistically, CST3 blocked the TGF-β receptor pathway, while GDF15 targeted the N-Myc signaling pathway.

Conclusions:

• CST3 and GDF15 exhibit significant anti-fibrotic properties in preclinical models of renal fibrosis.
• These cytokines represent promising candidates for the development of novel biopharmaceuticals to treat kidney fibrosis.
• Targeting TGF-β receptor and N-Myc pathways offers a potential mechanism for mitigating renal fibrosis.